WNT pathway in oral cancer: Epigenetic inactivation of WNT-inhibitors

Oncology Reports

Volumn 24, Issue 4, 2010, Pages 1035-1041

  Pannone, G ^a   Bufo, P ^a,b   Santoro, A ^a   Franco, R ^c   Aquino, G ^c   Longo, F ^c   Botti, G ^c   Serpico, R ^e   Cafarelli, B ^a   Abbruzzese, A ^e   Caraglia, M ^e   Papagerakis, S ^d   Lo Muzio, L ^a,b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

DKK 3; Methylation specific PCR; Oral cancer; SFRP 2; SFRP 4; SFRP 5; SFRP1; WIF 1; WNT pathway

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; PROTEIN; PROTEIN DKK 3; PROTEIN WIF 1; SFRP 1; SFRP 2; SFRP 4; SFRP 5; UNCLASSIFIED DRUG; WNT PROTEIN;

ACCURACY; ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE INACTIVATION; HUMAN; MALE; METHYLATION; MOUTH CARCINOMA; MUTATION; ORAL SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; EPIGENESIS, GENETIC; EYE PROTEINS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOUTH NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS;

EID: 77957374553     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000952     Document Type: Article

References (43)

1. Bovolenta P, Rodriguez J and Esteve P: Frizzled/RIK mediated signalling in axon guidance. Development 133: 4399-4408, 2006.
2. Veeman MT, Axelrod JD and Moon RT: A second canon. Functions and mechanisms of beta-catenin independent WNT signalling. Dev Cell 5: 367-377, 2003.
3. Gregorieff A and Clevers H: WNT signalling in the intestinal epithelium: from endoderm to cancer. Genes Dev 19: 877-890, 2005. (Pubitemid 40548056)
4. Taketo MM: Shutting down WNT signal-activated cancer. Nat Genet 36: 320-322, 2004.
5. Giles RH, van Es JH and Clevers H: Caught up in a WNT storm: WNT signalling in cancer. Biochim Biophys Acta 1653: 1-24, 2003.
6. Nusse R and Varmus HE: WNT genes. Cell 69: 1073-1087, 1992.
7. Cadigan KM and Nusse R: WNT signalling: a common theme in animal development. Genes Dev 11: 3286-3305, 1997.
8. Wodarz A and Nusse R: Mechanisms of WNT signalling in development. Annu Rev Cell Dev Biol 14: 59-88, 1998.
9. Rattner A, Hsieh JC, Smallwood PM, et al: A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc Natl Acad Sci USA 94: 2859-2863, 1997.
10. Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A and Aaronson SA: Interaction of frizzled related protein (FRP) with WNT ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of WNT signalling. J Biol Chem 274: 16180-16187, 1999.
11. Semënov MV, Tamai K, Brott BK, Kühl M, Sokol S and He X: Head inducer Dickkopf-1 is a ligand for WNT coreceptor LRP6. Curr Biol 11: 951-961, 2001.
12. Li L, Mao J, Sun L, Liu W and Wu D: Second cysteine-rich domain of Dickkopf-2 activates canonical WNT signalling pathway via LRP-6 independently of dishevelled. J Biol Chem 277: 5977-5981, 2002.
13. Tang Y, Simoneau AR, Liao WX, et al: WIF-1, a WNT pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Mol Cancer Ther 8: 458-468, 2009.
14. Clevers H: WNT/beta-catenin signalling in development and disease. Cell 127: 469-480, 2006.
15. Polakis P: The many ways of WNT in cancer. Curr Opin Gen Develop 17: 45-51, 2007.
16. Iwai S, Katagiri W, Kong C, Amekawa S, Nakazawa M and Yura Y: Mutations of the APC, beta-catenin and axin 1 genes and cytoplasmic accumulation of beta-catenin in oral squamous cell carcinoma. J Cancer Res Clin Oncol 131: 773-782, 2005.
17. Yamamoto H: Regulation of WNT signalling pathway and its relationship with tumorigenesis. Seikagaku 80: 1079-1093, 2008.
18. Takacs CM, Baird JR, Hughes EG, Kent SS, Benchabane H, Paik R and Ahmed Y: Dual positive and negative regulation of wingless signalling by adenomatous polyposis coli. Science 319: 333-336, 2008.
19. Aguilera O, Muñoz A, Esteller M and Fraga MF: Epigenetic alterations of the WNT/beta-catenin pathway in human disease. Endocr Metab Immune Disord Drug Targets 7: 13-21, 2007.
20. Ying Y and Tao Q: Epigenetic disruption of the WNT/beta-catenin signalling pathway in human cancers. Epigenetics 4: 307-312, 2009.
21. Lo Muzio L, Goteri G, Capretti R, et al: Beta-catenin gene analysis in oral squamous cell carcinoma. Int J Immunopathol Pharmacol 18: 33-38, 2005.
22. Gasparoni A, Chaves A, Fonzi L, Johnson GK, Schneider GB and Squier CA: Subcellular localization of beta-catenin in malignant cell lines and squamous cell carcinomas of the oral cavity. J Oral Pathol Med 31: 385-394, 2002.
23. Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Serpico R, Fanali S, De Rosa G, Piattelli A and Mariggiò MA: Delocalization in cell lines of oral cancer. Oral Oncol 38: 64-72, 2002.
24. Marur S and Forastiere AA: Head and neck cancer: changing epidemiology, diagnosis and treatment. Mayo Clin Proc 83: 489-501, 2008.
25. Braakhuis BJ, Brakenhoff RH and Leemans CR: A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med 33: 317-322, 2004.
26. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W and Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492, 1996.
27. Choi S and Myers JN: Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res 87: 14-32, 2008.
28. Imai T, Toyota M, Suzuki H, Akino K, Ogi K, Sogabe Y, Kashima L, Maruyama R, Nojima M, Mita H, Sasaki Y, Itoh F, Imai K, Shinomura Y, Hiratsuka H and Tokino T: Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci 99: 958-966, 2008.
29. Chung YL, Lee MY and Pui NNM: Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis 30: 1387-1397, 2009.
30. Lee SH, Kang HJ, Shin DH, Cho DY, Song JM, Lee HC, Kim GH, Song GA, Sol MY, Kim JY, Choi KU, Lee CH, Huh GY and Park do Y: Expression of beta-catenin and its mechanism of delocalization in intestinal-type early gastric cancer based on mucin expression. Histol Histopathol 24: 831-838, 2009.
31. Pannone G, Lo Muzio L, Bucci P, Canfora M, Pannone G, Santacroce L, Bucci T and Staibano S: Physiopathology of beta- and gamma-catenin expression in the oral epithelium. Minerva Stomatol 47: 583-588, 1998.
32. Lo Muzio L, Staibano S, Pannone G, Grieco M, Mignogna MD, Cerrato A, Testa NF and De Rosa G: B- and gamma-catenin expression in oral squamous cell carcinomas. Anticancer Res 19: 3817-3826, 1999.
33. Mahomed F, Altini M and Meer S: Altered E-cadherin/(beta)- catenin expression in oral squamous carcinoma with and without nodal metastasis. Oral Dis 13: 386-392, 2007.
34. Cai ZG, Shi XJ, Gao Y, Wei MJ, Wang CY and Yu GY: Bcatenin expression pattern in primary oral squamous cell carcinoma. Chin Med J 121: 1866-1870, 2008.
35. Sogabe Y, Suzuki H, Toyota M, Ogi K, Imai T, Nojima M, Sasaki Y, Hiratsuka H and Tokino T: Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int J Oncol 32: 1253-1261, 2008.
36. Bovolenta P, Esteve P, Ruiz JM, Cisneros E and Lopez-Rios J: Beyond WNT inhibition: new functions of Frizzled-related proteins in development and disease. J Cell Sci 121: 737-746, 2008.
37. Turashvili G, Bouchal J, Burkadze G and Kolar Z: WNT signalling pathway in mammary gland development and carcinogenesis. Pathobiology 73: 213-223, 2006.
38. Zhou Z, Wang J, Han X, Zhou J and Linder S: Up-regulation of human secreted frizzled homolog in apoptosis and its downregulation in breast tumors. Int J Cancer 78: 95-99, 1998.
39. To KF, Chan MW, Leung WK, Yu J, Tong JH, Lee TL, Chan FK and Sung JJ: Alterations of frizzled (FzE3) and secreted frizzled related protein (hSFRP) expression in gastric cancer. Life Sci 70: 483-489, 2001.
40. Ko J, Ryu KS, Lee YH, Na DS, Kim YS, Oh YM, Kim IS and Kim JW: Human secreted frizzled-related protein is downregulated and induces apoptosis in human cervical cancer. Ex Cell Res 280: 280-287, 2002.
41. Huang J, Zhang YL, Teng XM, Lin Y, Zheng DL, Yang PY and Han ZG: Down-regulation of SFRP-1 as a putative tumor suppressor gene can contribute to human hepatocellular carcinoma. BMC Cancer 7: 126, 2007.
42. Zi X, Guo Y, Simoneau AR, Hope C, Xie J, Holcombe RF and Hoang BH: Expression of Frzb/secreted Frizzled-related protein 3, a secreted WNT antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness. Cancer Res 65: 9762-9770, 2005.
43. Rubin JS, Barshishat-Kupper M, Feroze-Merzoug F and Xi ZF: Secreted WNT antagonists as tumor suppressors: pro and con. Fron Biosci 11: 2093-2105, 2006.